Summary To determine whether undercarboxylated osteocalcin (UC-OC) or gamma-carboxyglutamic-carboxylated-type osteocalcin (GLA-OC) concentrations deviate from normal in type 1 diabetes (T1D), serum levels were compared between 115 subjects with T1D and 55 age-matched healthy controls.
Introduction
Type 1 diabetes (T1D), unlike type 2 diabetes (T2D), is a condition in which insulin sensitivity remains generally intact, but absolute insulin deficiency develops, secondary to progressive, autoimmune-mediated pancreatic ß-cell destruction [1] . Moreover, a relative IGF-1 deficiency co-exists in this disorder [2] . Diabetic osteopathy is a significant co-morbidity of T1D [3] , characterized by osteoporosis, increased risk for bone fracture, and microarchitectural changes that increase the brittleness of bone [4] . Chronic hyperglycemia, hypoinsulinemia, disruption of the growth hormone (GH)/IGF-1/IGFBP system, and altered vitamin/mineral homeostasis are all thought to contribute to this skeletal pathology [3, 5] . However, the specific interplay between osteoblast function and skeletal integrity in T1D is less clear.
Osteocalcin (OC) is a bone-specific protein product of osteoblasts, osteocytes and odontoblasts. Intracellular proosteocalcin undergoes posttranslational modification by the vitamin K-and CO 2 -dependent synthesis of three gamma-carboxyglutamic (GLA) residues, allowing for α-helical conformation of the protein, a prerequisite for osteocalcin to adsorb to calcium ions on hydroxyapatite crystals in bone [6] . Hence, carboxylated-type osteocalcin (GLA-OC) accumulates in bone [7] . In contrast, undercarboxylated osteocalcin (UC-OC), with less than three carboxylated GLA residues, does not undergo α-helical conformation and has lesser affinity for Ca 2+ and hydroxyapatite. Therefore, while both forms of OC are found in bone, concentrations of total OC in the systemic circulation are relatively smaller, with a greater proportion of serum OC being the undercarboxylated form [8] .
Studies which report alterations in serum OC concentrations in various skeletal, as well as non-skeletal diseases are numerous [6] . Physiological variations in OC concentrations are also recognized. Specifically, it is known that serum concentrations of OC and UC-OC are higher in children and adolescents [9] , and exhibit diurnal variation, being higher in the early morning than in the late afternoon [9] [10] [11] .
Recently, a direct in vitro stimulatory effect of osteocalcin on insulin expression and secretion by pancreatic islet cells cultured from wild-type mice has been demonstrated [12, 13] . Consistent with these findings, osteoblast-specific Esp −/− mice, an osteocalcin gain-of-function model, are thought to exhibit increased pancreatic ß-cell proliferation, increased insulin secretion and improved insulin sensitivity, leading to fasting hypoglycemia [13] . Inversely, transgenic mice overexpressing Esp, or osteocalcin knockout mice (Ocn −/− ) display the opposite metabolic phenotype, specifically decreased ß-cell proliferation and glucose intolerance [13] . These observations have not, as yet, been corroborated in humans by genetically informative clinical conditions. However, cross-sectional studies in humans have demonstrated an association of higher serum UC-OC concentrations with improved glucose tolerance in middle-aged men [14] as well as in patients with T2D [15] .
In the present study, we conducted an analysis to answer a related physiological question; specifically, in a condition of absolute insulin deficiency, can dysregulation of circulating concentrations of UC-OC, GLA-OC, or the ratio of UC-OC to GLA-OC be demonstrated. If animal model data is reflective of the human condition, we hypothesized that compensatory upregulation of UC-OC should occur in patients with T1D (i.e., insulin deficiency with normal insulin sensitivity), and specifically in those with suboptimal glycemic control. To examine this question, first-morning, fasting serum concentrations of UC-OC and GLA-OC were compared between T1D subjects and age-matched healthy control subjects.
Research design and methods

Study population
Subjects with T1D and age-matched healthy control subjects, ages 14-40 years, were recruited from clinics at the University of Arkansas for Medical Sciences (UAMS), Arkansas Children's Hospital and surrounding communities. Approval was obtained from the Institutional Review Board of UAMS and all subjects provided informed consent (18-40 years) or assent with parental consent (14-17 years). Exclusion criteria included: (1) T2D; (2) history of other chronic systemic inflammatory or autoimmune disease or malignancy; (3) pregnancy; (4) concurrent ketonuria; (5) active infection; or (6) concurrent use of oral glucocorticoid therapy for any reason. Additionally, no subject had evidence of skeletal injury at the time of evaluation.
For all subjects, two first-morning, outpatient evaluations were conducted 3-5 days apart, allowing us to obtain: (1) demographic information and medical history, including insulin daily dose (IDD); (2) two separate fasting venipuncture laboratory measurements of fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), and C-peptide; and (3) a 3-day interval recording of continuous glucose monitor sensor data (using the Medtronic Minimed® CGMS, MMT-7102, Northridge, CA), indicative of integrated, concurrent glycemic control. Due to specimen volume limitations, serum from visit 1 was used for measurement of GLA-OC, UC-OC, adiponectin (Acrp30), leptin, insulin-like growth factor 1 (IGF-1), and for quantification of type 1 collagen degradation fragments (CTX); serum from visit 2 was used for measurement of total calcium, 25-hydroxy vitamin D (25OHD), and intact parathyroid hormone (PTH), as previously reported [5] . No effort was made to control for or assess dietary calcium or vitamin D intake. However, concurrent medication use, including calcium or vitamin D supplements, was recorded.
Assays FPG and C-peptide were measured by the UAMS General Clinical Research Center Core Laboratory. HbA1c was measured by LabCorp (Dallas, TX). Serum measurements of total calcium (reference range, 8.4-10.2 mg/dl), intact PTH (reference range, 15-75 pg/ml; electrochemiluminescent immunoassay), and 25OHD (reference range, optimal level 30-80 ng/ml; insufficiency 20-29 ng/ml; deficiency <20 ng/ml; competitive immunoluminometry) were performed at ARUP Laboratories (Salt Lake City, UT). IGF-1 was measured using the Active IGF-1 ELISA (#DSL-10-5600, Diagnostic Systems Laboratories, Inc., Webster, TX). UC-OC and GLA-OC were measured using Takara Bio Inc., EIA kits (MK118 and MK111, respectively, Madison, WI). As a measure of bone resorption, degradation products of type 1 collagen (CTX) were measured using the serum CrossLAPs ELISA (AC-02F1, Immunodiagnostic Systems, Inc., Scottsdale, AZ). Additionally, concentrations of leptin and adiponectin, as both directly proportional (leptin) and inversely proportional (adiponectin) markers of total body fat mass, were measured using the MILLIPLEX MAP serum adipokine panel B multiplex assay (HADK2-61-B, Millipore Corp. Billerica, MA) and a human total adiponectin ELISA (DRP300, R & D Systems, Inc., Minneapolis, MN), respectively.
Statistical analyses
Statistical analysis was performed using R software (version 2.12.1; R Development, 2010) and SPSS Statistical software (version 18.0; SPSS Inc., Chicago, ILL). Results for FPG, HbA1c, and C-peptide obtained from the two study visits were averaged. Concentrations of UC-OC, GLA-OC, IGF-1, CTX, calcium, PTH, 25OHD, adiponectin, and leptin were measured only once per subject. The ratio of UC-OC to GLA-OC (U/G ratio), the ratio of C-peptide to FPG (C-peptide/glucose ratio) and the ratio of adiponectin to leptin (A/L ratio) were also calculated. Kruskal-Wallis nonparametric tests were used to ascertain differences between multiple groups whereas Mann-Whitney U tests were used for specific two-group comparisons. Spearman's rank correlation coefficients were assessed to estimate correlation between variables of interest. We also used a linear regression model, incorporating the pertinent interaction terms with group (control and T1D) to identify group difference of associations between dependent and independent variables of interest. If necessary, monotonous transformations (e.g., log transformations) of variables were used. Additionally, possible predictor and confounding variables were modeled in a multivariate regression, to identify those factors that best predicted the outcome variable, specifically UC-OC or GLA-OC. Data are presented as median and range for continuous variables. For all analyses, a statistically significant difference was defined by p≤0.05.
Results
The study population included 55 control subjects and 115 subjects with T1D. Clinical characteristics of the study population are shown in Table 1 . Aspects of this study population have also been reported elsewhere [5, 16] . Control and T1D groups were comparable with respect to gender (56% vs. 53% female, respectively), racial distribution (86% vs. 93% Caucasian, respectively), and baseline BMI (25.2±4.7 vs. 24.9±4.4 kg/m 2 , respectively). No subjects were receiving oral calcium supplements or vitamin K treatment whereas eight subjects (two controls and six T1D) reported daily intake of a generic multivitamin containing vitamin D. Of the T1D subjects, 99 subjects were categorized as normoalbuminuric at the time of evaluation (24-h urinary albumin excretion (UAE), ≤30 mg/g Cr) while UAE concentrations were within a microalbuminuria range in 14 subjects (UAE, >30-299 mg/g Cr) and within a macroalbuminuria range (UAE, ≥300 mg/g Cr) in two subjects [5] .
Serum UC-OC, GLA-OC, CTX, adiponectin, and leptin concentrations were first compared between control and T1D subgroups, and further examined by gender, age, and level of glycemic control. No statistically significant differences in concentration of UC-OC, GLA-OC, U/G ratio, CTX, or leptin were observed between the T1D and control populations (Table 2) . Adiponectin concentrations were, however, significantly higher in the T1D subgroup, and consistent with this, the A/L ratio was also significantly higher in the T1D group (median (range); control, 1.54 (0.55, 25.79) vs. T1D: 2.08 (1.44, 61.64); p=0.02). When T1D subjects alone were subdivided into those with HbA1c of <7.5% vs. those with HbA1c of ≥7.5%, adiponectin levels were also higher in subjects with poorer glycemic control (<7.5%-10.43 μg/mL (3.91, 25.22) Mean UC-OC, GLA-OC, and CTX concentrations were higher in male subjects, while adiponectin and leptin were higher in females (Table 2 ). These gender specific differences were maintained within the T1D subgroup for UC-OC (p=0.01), GLA-OC (p=0.002), CTX (p< 0.001), adiponectin (p=0.04), and leptin (p<0.0001) but only for CTX (p=0.003), adiponectin (p=0.005), and leptin (p<0.001) within the control group. (Of note, mean UC-OC and GLA-OC concentration were also consistently higher in control male subjects, but the difference was not statistically significant).
Also, UC-OC, GLA-OC, U/G ratio, CTX and adiponectin concentrations were significantly higher in subjects <18 years of age (Table 2 ). Age differences were maintained within the T1D subgroup for UC-OC (p<0.001), GLA-OC (p=0.001), and CTX (p<0.0001) but not for adiponectin. Age differences were maintained within the control subgroup for UC-OC (p<0.001), U/G ratio (p=0.01) and CTX (p<0.0001) but not for GLA-OC or adiponectin.
Relationships between UC-OC, GLA-OC, or CTX (as dependent variable) and: (1) indices of glycemic control (HbA1c, fasting plasma glucose, CGMS glucose, IDD, and C-peptide/glucose); (2) indices of skeletal homeostasis (total Ca, 25OHD, PTH, IGF-1, and CTX); and (3) patient phenotype parameters (age, adiponectin, and leptin) were then explored. Correlations between paired variables of interest are shown in Table 3 . In both the control and T1D subgroups, UC-OC concentrations were strongly positively correlated with IGF-1 and CTX concentrations, yet negatively correlated with age. GLA-OC concentrations were positively correlated with IGF-1 and PTH.
In the T1D subgroup specifically, UC-OC concentrations were positively correlated with: (1) C-peptide/glucose ratio (reflective of endogenous insulin secretion), (2) IGF-1 (indicative of intra-portal insulin sufficiency, and with (3) total IDD. UC-OC concentrations were also inversely correlated with BMI and leptin, but not correlated with HbA1c, mean fasting glucose, mean CGMS glucose, adiponectin, or the A/L ratio. Hence, in a population of patients without insulin resistance, UC-OC correlated positively with markers of insulin exposure, either endogenously produced or exogenously administered and negatively with higher body fat. GLA-OC concentrations in the T1D subgroup were positively correlated with IGF-1, PTH, 25-OHD, and CTX, while being negatively correlated with age. Finally, a significant group difference of association (interaction) was confirmed between UC-OC and C-peptide/ glucose (p=0.04), between GLA-OC and CTX (p=0.02), and between GLA-OC and age (p=0.05).
To determine those factors most strongly affecting plasma UC-OC or GLA-OC concentrations, we performed multivariate regression modeling, using group (control vs. T1D), gender, age, PTH, HbA1c, CGMS glucose, IGF-1, 25OHD, CTX, leptin, and adiponectin as covariates. After backward elimination from the full model set, significant correlates of UC-OC included CTX (p<0.001, ß-coefficient =0.516), subject age (p<0.001, ß-coefficient=−0.248), and HbA1c value (p=0.013, ß-coefficient=−0.141) with a multiple R 2 =0.542. IGF-1 concentrations were marginally related to UC-OC (p=0.086, ß-coefficient=0.109). Specifically, being younger, having higher CTX and lower HbA1c values, and possibly a higher IGF-1 concentration all contributed to a higher UC-OC.
Significant correlates of GLA-OC included CTX (p< 0.001, ß-coefficient = 0.412), HbA1c (p = 0.009, ß-coefficient = 0.247), 25OHD (p = 0.001, ß-coefficient = 0.221), PTH (p=0.005, ß-coefficient=0.189), IGF-1 (p= 0.039, ß-coefficient=0.147), and gender (p=0.029, ß-coefficient=0.147) with a multiple R 2 =0.411. Specifically, higher CTX, HbA1c, 25OHD, PTH, and IGF-1 levels were all associated with higher GLA-OC concentrations; additionally, male gender contributed to a higher GLA-OC. 
NS
Concentrations of UC-OC, GLA-OC, the ratio of UC-OC to GLA-OC, CTX, adiponectin and leptin are compared between: (1) control and T1D subjects; (2) male and female subjects; and (3) subjects <18 and ≥18 years of age. All data are expressed as median (range)
Discussion
In contrast to our hypothesis, concentrations of UC-OC and GLA-OC were not statistically different between T1D and control populations; and specifically, concentrations of UC-OC were not significantly elevated in the T1D group. In fact, by multivariate analysis, having a higher HbA1c, reflective of poorer glycemic control, was correlated with a lower UC-OC but inversely with a higher GLA-OC. Additionally, UC-OC was inversely correlated with duration of disease (R=−0.299, p=0.001), suggesting that longer duration of T1D related to a lower UC-OC. Consistent with our findings, an inverse association of UC-OC with HbA1c has very recently been demonstrated in a population of over 1,500 elderly Japanese men, some with T2D [17] , as well as in a population of 180 men, all with T2D [15] . Additionally, an inverse correlation of total OC with HbA1c has also been demonstrated in children with T1D [18, 19] . Expected gender and age-based differences for UC-OC, GLA-OC, and leptin [20] [21] [22] [23] were confirmed within our overall study population, as well as within the T1D subgroup. Adiponectin concentrations were also higher in females, both overall and in T1D. Moreover, adiponectin levels were marginally higher in subjects under 18 years of age, though this age difference was not maintained with the T1D group. Increased plasma concentrations of adiponectin have been reported in Japanese adults with T1D [22] while in US pediatric subjects with T1D and in adults with Latent autoimmune diabetes [24] , adiponectin levels were not different from those in similarly aged healthy control subjects [25] . Of note, in our study, the age range (14-40 years) crosses both the pediatric and adult classification, perhaps accounting for our failure to identify differences in adiponectin concentration between a younger and older T1D cohort; none-the-less, overall, adiponectin levels were higher in T1D subjects. To our knowledge, however, gender and age differences for UC-OC and GLA-OC in T1D subjects specifically, have not been demonstrated previously.
Disease-based alterations in either adiponectin or leptin concentrations in T1D, T2D, or as they relate to glucose homeostasis, have been examined extensively by others [24] [25] [26] [27] , and recreation of these findings was not the intent of our study. Rather, we were interested in examining possible interactions of adiponectin or leptin with UC-OC and GLA-OC concentrations in T1D. Studies in genetically modified mice suggest that UC-OC has a direct affect on Spearman rank correlation was assessed as a measure of association between paired variables of interest (delineated in Results). Data are shown for those associations in which at least one subgroup analysis (control or T1D) was statistically significant, set in italics N/A not applicable *p=0.04, a significant group difference of association (interaction) was confirmed between UC-OC and C-peptide/glucose, between GLA-OC and CTX (p=0.02), and between GLA-OC and age (p=0.05) adipose tissue to induce adiponectin production, but not leptin [28] . Also, an inverse correlation between carboxylated osteocalcin and high molecular weight adiponectin has been reported in healthy children [29] . Surprisingly, in the current studies, neither UC-OC nor GLA-OC concentrations were related to adiponectin levels or to the A/L ratio, either by correlation analysis or by multivariate modeling, either overall, or in the T1D subgroup. In contrast, leptin was negatively correlated with UC-OC but only in T1D subjects. Thus, the interaction of UC-OC with adipokines in humans appears to be more complex than that described in rodents, and these interactions may be different in T1D than in non-diabetic subjects. In vitro, insulin can up-regulate osteocalcin expression in osteoblasts, through inhibiting the forkhead transcription factor, FoxO1 [30] . Furthermore, in genetically modified mice, insulin signaling in osteoblasts appears to enhance osteoclast activity and osteoclasts, in turn, decarboxylate OC [31] . Thus, in mice, when insulin signals in osteoblasts, systemic UC-OC production is increased [31] . The current studies address this consideration in humans by showing that in type 1 diabetes, UC-OC concentrations were associated with C-peptide/glucose ratio (i.e., endogenously secreted insulin) and with the total daily dose of insulin (i.e., exogenously administered insulin). Interestingly, the Cpeptide/glucose ratio was not significantly associated with UC-OC in non-diabetic subjects. Nonetheless, the associations in T1D are consistent with the reported effects of insulin on bone-derived UC-OC. Moreover, in both control and T1D groups, serum IGF-1 concentrations were strongly associated with GLA-OC and UC-OC, suggesting that IGF-1, an insulin homolog, also plays a significant role in controlling OC serum concentrations, irrespective of the underlying insulin dynamics.
We also observed a very strong relationship between UC-OC and CTX, both by paired comparisons (Table 3) , as well as multivariate regression modeling, supporting a role for bone resorption in the decarboxylation of osteocalcin, as has been suggested by others [32] .
Alternatively, this association may reflect coupling between bone resorption and bone formation, as has been suggested by studies demonstrating correlation of CTX with total OC in individuals with T1D [33] . Consistent with this, we observed a highly significant, though weaker correlation between GLA-OC and CTX in T1D.
A primary limitation of this study is the fact that it was conducted as a retrospective analysis of a preexisting specimen and data set. As such, this analysis represents a cross-sectional, single point-in-time assessment of skeletal and glycemic status. Moreover, we do not have an assessment of bone mineral density available in this dataset. Racial diversity of the study population is also limited, though the racial distribution is comparable across the control and T1D study groups, and not appreciably inconsistent with demographic expectations for type 1 diabetes [34] . However, the study group is relatively large, and sufficient in size to confirm many expected physiological determinants of UC-OC and GLA-OC.
In summary, since UC-OC has been shown to increase insulin production and beta cell expansion in mice [31] , we anticipated that UC-OC might be elevated in T1D as a compensatory mechanism to improve endogenous insulin production; instead, we found that UC-OC concentrations were similar in control and T1D individuals. However, in T1D, the association of UC-OC serum concentrations with either endogenous production of insulin or exogenous administration of insulin suggests that UC-OC may, at least in part, be regulated through insulin-mediated events. Other parameters also showed strong associations with UC-OC, GLA-OC, or with both, including: age, CTX, HbA1c, IGF-1, PTH, and 25OHD, confirming that UC-OC and GLA-OC are regulated by a variety of developmental and metabolic pathways, irrespective of insulin status.
